



# XVII INTERNATIONAL AIDS CONFERENCE

3-8 August 2008 | Mexico City

## Poster Exhibition

### Track C - Monitoring and evaluation

#### TUPE0353 - Low level of virological failure and drug resistance among patients receiving antiretroviral treatment under programme conditions in Maputo, Mozambique

F. Maldonado<sup>1</sup>, M. Biot<sup>1</sup>, F. Roman<sup>2</sup>, C. Masquelier<sup>2</sup>, M. Anapenge<sup>3</sup>, R. Bastos<sup>4</sup>, H.C. Chuquela<sup>5</sup>, V. Arendt<sup>2</sup>, J.C. Schmit<sup>2</sup>, R. Zachariah<sup>6</sup>

<sup>1</sup>Medecins sans Frontieres, Maputo, Mozambique, <sup>2</sup>Retrovirology Laboratory, Centre de Recherche Public de la Santé, Luxembourg, Luxembourg, <sup>3</sup>Central Hospital Maputo- MoH Mozambique, Maputo, Mozambique, <sup>4</sup>Central Hospital Maputo- MoH Mozambique, Dermatology, Maputo, Mozambique, <sup>5</sup>Primeiro de Maio Health Centre - City Health Authority-Mozambique, Maputo, Mozambique, <sup>6</sup>Medecins sans Frontieres, Operational Research, Brussels Operational Centre, Brussels, Belgium

**Setting:** Primeiro-de-Maio day clinic, Maputo, Mozambique.

**Objectives:** Within a sample of individuals placed on first-line ART, we report on

- the feasibility of viral load monitoring using dried plasma spots (DPS) as a surveillance tool for programme performance in a setting where routine viral load is unavailable,
- the proportion of patients with virological failure and
- drug resistance patterns.

**Design:** Cross-sectional survey.

**Methods:** HIV-1 RNA viral load levels were determined using qualitative RNA-polymerase chain reaction and resistance mutations were sequenced using drug genotyping. The study was conducted between June and December 2006 in a sample of ART-naïve patients who had been on treatment for over one year.

**Results:** 149 consecutive patients (69% females, median age: 36.4 years) were included after a mean follow-up time of 23 months. 117(78.5%, 95% confidence interval CI: 71-85) patients had undetectable (<400copies/ml) viral loads, while in 32 (21%, 95% CI: 14-28) this was detectable (range 437-58,884 copies/ml). Among those with virological failure only 4(12.5%) patients were failing clinically and 3(9%) immunologically.

Of 15 patients with viral loads above 1,000 copies/ml, twelve viruses could be sequenced and included 8 C subtypes and 4 circulating recombinant forms CRF08. Eight (5% 95% CI: 2-9) of 32 patients with detectable viral loads had one or more major resistance mutations. Nucleoside reverse transcriptase inhibitor (NRTI) and Non-NRTI mutations were observed. There were no major mutations for resistance to protease inhibitors.

**Conclusions:** Among individuals placed on a first-line ART under programme conditions, the level of virological failure and drug resistance is reassuringly low. In resource-limited settings embarking on ART scale-up without access to routine viral load assays, punctual viral load surveys and targeted genotyping are useful to monitor programme quality and the circulation of HIV-drug-resistance strains.

Presenting author email: [bastos\\_rui@yahoo.com](mailto:bastos_rui@yahoo.com)